Coagulation factor VIIa binds to herpes simplex virus 1-encoded glycoprotein C forming a factor X-enhanced tenase complex oriented on membranes. 2020

Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
Center for Innovation, Canadian Blood Services, Vancouver, BC, Canada.

The cell membrane-derived initiators of coagulation, tissue factor (TF) and anionic phospholipid (aPL), are constitutive on the herpes simplex virus type 1 (HSV1) surface, bypassing physiological regulation. TF and aPL accelerate proteolytic activation of factor (F) X to FXa by FVIIa to induce clot formation and cell signaling. Thus, infection in vivo is enhanced by virus surface TF. HSV1-encoded glycoprotein C (gC) is implicated in this tenase activity by providing viral FX binding sites and increasing FVIIa function in solution. To examine the biochemical influences of gC on FVIIa-dependent FX activation. Immunogold electron microscopy (IEM), kinetic chromogenic assays and microscale thermophoresis were used to dissect tenase biochemistry. Recombinant TF and gC were solubilized (s) by substituting the transmembrane domain with poly-histidine, which could be orientated on synthetic unilamellar vesicles containing Ni-chelating lipid (Ni-aPL). These constructs were compared to purified HSV1 TF±/gC ± variants. IEM confirmed that gC, TF, and aPL are simultaneously expressed on a single HSV1 particle where the contribution of gC to tenase activity required the availability of viral TF. Unlike viral tenase activity, the cofactor effects of sTF and sgC on FVIIa was additive when bound to Ni-aPL. FVIIa was found to bind to sgC and this was enhanced by FX. Orientation of sgC on a lipid membrane was critical for FVIIa-dependent FX activation. The assembly of gC with FVIIa/FX parallels that of TF and may involve other constituents on the HSV1 envelope with implications in virus infection and pathology.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D005170 Factor X Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder. Autoprothrombin III,Coagulation Factor X,Stuart Factor,Stuart-Prower Factor,Blood Coagulation Factor X,Factor 10,Factor Ten,Stuart Prower Factor,Factor X, Coagulation
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D015942 Factor VIIa Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation. Coagulation Factor VIIa,Factor VII, Activated,Blood Coagulation Factor VII, Activated,Factor 7A,Factor Seven A,Activated Factor VII,Factor VIIa, Coagulation
D018259 Herpesvirus 1, Human The type species of SIMPLEXVIRUS causing most forms of non-genital herpes simplex in humans. Primary infection occurs mainly in infants and young children and then the virus becomes latent in the dorsal root ganglion. It then is periodically reactivated throughout life causing mostly benign conditions. HSV-1,Herpes Simplex Virus 1,HHV-1,Herpes Simplex Virus Type 1,Herpesvirus 1 (alpha), Human,Human Herpesvirus 1

Related Publications

Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
November 2004, Thrombosis and haemostasis,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
January 2006, The Biochemical journal,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
January 2005, The Journal of general virology,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
December 1987, Microbial pathogenesis,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
September 1983, Journal of virology,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
December 1997, Uirusu,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
April 1989, Proceedings of the National Academy of Sciences of the United States of America,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
February 2024, Journal of theoretical biology,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
September 2002, The Journal of biological chemistry,
Bryan H Lin, and Michael R Sutherland, and Federico I Rosell, and James H Morrissey, and Edward L G Pryzdial
February 2020, Journal of virology,
Copied contents to your clipboard!